Literature DB >> 14638392

Vaccines and animal models for arboviral encephalitides.

Aysegul Nalca1, Patricia F Fellows, Chris A Whitehouse.   

Abstract

Arthropod-borne viruses ("arboviruses") cause significant human illness ranging from mild, asymptomatic infection to fatal encephalitis or hemorrhagic fever. The most significant arboviruses causing human illness belong to genera in three viral families, Togaviridae, Flaviviridae, and Bunyaviridae. These viruses represent a significant public health threat to many parts of the world, and, as evidenced by the recent introduction of the West Nile virus (WNV) to the Western Hemisphere, they can no longer be considered specific to any one country or region of the world. Like most viral diseases, there are no specific therapies for the arboviral encephalitides; therefore, effective vaccines remain the front line of defense for these diseases. With this in mind, the development of new, more effective vaccines and the appropriate animal models in which to test them become paramount. In fact, for many important arboviruses (e.g. California serogroup and St. Louis encephalitis viruses), there are currently no approved vaccines available for human use. For others, such as the alphaviruses, human vaccines are available only as Investigational New Drugs, and thus are not in widespread use. On the other hand, safe and effective vaccines against tick-borne encephalitis virus (TBEV) and Japanese encephalitis virus (JEV) have been in use for decades. New challenges in vaccine development have been met with new technologies in vaccine research. Many of the newer vaccines are now being developed by recombinant DNA technology. For example, chimeric virus vaccines have been developed using infectious clone technology for many of the arboviruses including, WNV, JEV, and TBEV. Other successful approaches have involved the use of naked DNA encoding and subsequently expressing the desired protective epitopes. Naked DNA vaccines have been used for TBEV and JEV and are currently under development for use against WNV. The development of less expensive, more authentic animal models to evaluate new vaccines against arboviral diseases will become increasingly important as these new approaches in vaccine research are realized. This article reviews the current status of vaccines, both approved for use and those in developmental stages, against the major arboviral encephalitides causing human disease. In addition, research on animal models, both past and present, for these diseases are discussed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14638392     DOI: 10.1016/j.antiviral.2003.08.001

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  12 in total

1.  Orthobunyavirus entry into neurons and other mammalian cells occurs via clathrin-mediated endocytosis and requires trafficking into early endosomes.

Authors:  Bradley S Hollidge; Natalia B Nedelsky; Mary-Virginia Salzano; Jonathan W Fraser; Francisco González-Scarano; Samantha S Soldan
Journal:  J Virol       Date:  2012-05-23       Impact factor: 5.103

2.  Discovery of Tick-Borne Karshi Virus Implies Misinterpretation of the Tick-Borne Encephalitis Virus Seroprevalence in Northwest China.

Authors:  Yuan Bai; Yanfang Zhang; Zhengyuan Su; Shuang Tang; Jun Wang; Qiaoli Wu; Juan Yang; Abulimiti Moming; Yujiang Zhang; Lesley Bell-Sakyi; Surong Sun; Shu Shen; Fei Deng
Journal:  Front Microbiol       Date:  2022-05-03       Impact factor: 6.064

3.  Cysteine-free proteins in the immunobiology of arthropod-borne diseases.

Authors:  J Santiago Mejia; Erik N Arthun; Richard G Titus
Journal:  J Biomed Biotechnol       Date:  2010-01-04

4.  Partially neutralizing potency against emerging genotype I virus among children received formalin-inactivated Japanese encephalitis virus vaccine.

Authors:  Yi-Chin Fan; Jo-Mei Chen; Hsien-Chung Chiu; Yi-Ying Chen; Jen-Wei Lin; Chen-Chang Shih; Chih-Ming Chen; Chao-Chin Chang; Gwong-Jen J Chang; Shyan-Song Chiou
Journal:  PLoS Negl Trop Dis       Date:  2012-09-27

5.  Pathogenicity of two recent Western Mediterranean West Nile virus isolates in a wild bird species indigenous to Southern Europe: the red-legged partridge.

Authors:  Elena Sotelo; Ana Valeria Gutierrez-Guzmán; Javier del Amo; Francisco Llorente; Mehdi El-Harrak; Elisa Pérez-Ramírez; Juan Manuel Blanco; Ursula Höfle; Miguel Angel Jiménez-Clavero
Journal:  Vet Res       Date:  2011-01-18       Impact factor: 3.683

6.  Development of a model of Saint Louis encephalitis infection and disease in mice.

Authors:  Rafael Elias Marques; Juliana L Del Sarto; Rebeca P F Rocha; Giovanni F Gomes; Allysson Cramer; Milene A Rachid; Danielle G Souza; Maurício L Nogueira; Mauro M Teixeira
Journal:  J Neuroinflammation       Date:  2017-03-22       Impact factor: 8.322

7.  ZIKV Demonstrates Minimal Pathologic Effects and Mosquito Infectivity in Viremic Cynomolgus Macaques.

Authors:  Sasha R Azar; Shannan L Rossi; Sherry H Haller; Ruimei Yun; Jing H Huang; Jessica A Plante; Jiehua Zhou; Juan P Olano; Christopher M Roundy; Kathryn A Hanley; Scott C Weaver; Nikos Vasilakis
Journal:  Viruses       Date:  2018-11-21       Impact factor: 5.048

Review 8.  Comparative Pathology of West Nile Virus in Humans and Non-Human Animals.

Authors:  Alex D Byas; Gregory D Ebel
Journal:  Pathogens       Date:  2020-01-07

Review 9.  Neurological Sequelae Resulting from Encephalitic Alphavirus Infection.

Authors:  Shannon E Ronca; Kelly T Dineley; Slobodan Paessler
Journal:  Front Microbiol       Date:  2016-06-20       Impact factor: 5.640

Review 10.  Pre-spillover prevention of emerging zoonotic diseases: what are the targets and what are the tools?

Authors:  J E Childs
Journal:  Curr Top Microbiol Immunol       Date:  2007       Impact factor: 4.291

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.